摘要
目的探讨羟苯磺酸钙胶囊联合玻璃体注射康柏西普治疗非增殖期糖尿病视网膜病变的效果。方法选取2018年1月至2020年1月收治的90例非增殖期糖尿病视网膜病变患者作为研究对象,随机将其分为对照组和观察组,各45例。对照组采用羟苯磺酸钙胶囊治疗,观察组采用羟苯磺酸钙胶囊联合玻璃体注射康柏西普治疗。比较两组氧化应激指标、视网膜中央动脉血流、最佳矫正视力及黄斑中心厚度。结果治疗后,观察组的MDA、AOPP水平低于对照组,TAC水平高于对照组(P<0.05)。治疗后,观察组PSV、EDV高于对照组(P<0.05)。治疗后,观察组最佳矫正视力高于对照组,黄斑中心厚度低于对照组(P<0.05)。结论羟苯磺酸钙胶囊联合玻璃体注射康柏西普治疗非增殖期糖尿病视网膜病变患者能够减轻氧化应激反应,提高视网膜中央动脉血流改善效果,促进病情恢复,值得推广。
Objective To explore the effect of calcium dobesilate capsules combined with vitreous injection of conbercept in the treatment of non-proliferative diabetic retinopathy.Methods Ninty patients with non-proliferative diabetic retinopathy admitted from January 2018 to January 2020 were selected as the study objects,and the patients were randomly divided into control group and observation group,with 45 cases in each group.The control group was treated with calcium dobesilate capsules,and the observation group was treated with calcium dobesilate capsules combined with vitreous injection of conbercept.The indexes of oxidative stress,central retinal artery blood flow,best corrected visual acuity and central macular thickness were compared between the two groups.Results After treatment,the levels of MDA and AOPP of the observation group were lower than those of the control group,and TAC level was higher than that of the control group(P<0.05).After treatment,PSV and EDV of the observation group were higher than those of the control group(P<0.05).After treatment,the best corrected visual acuity of the observation group was higher than that of the control group,and the central macular thickness was lower than that of the control group(P<0.05).Conclusion The calcium dobesilate capsules combined with vitreous injection of conbercept in the treatment of patients with non-proliferative diabetic retinopathy can reduce oxidative stress reaction,enhance the improvement effect of central retinal artery blood flow,and promote the recovery of the disease,which is worthy of promotion.
作者
穆泽辰
MU Zechen(Ophthalmic Fundus Disease Department,Anyang Eye Hospital,Anyang 455000,China)
出处
《临床医学研究与实践》
2021年第5期54-56,共3页
Clinical Research and Practice